Photodynamic therapy for polypoidal choroidal vasculopathy: baseline perimetric results and visual outcomes.
OBJECTIVE
To investigate whether the baseline mean deviation (MD) of Humphrey perimetry has a predictive value for visual improvement after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV).


METHODS
We retrospectively reviewed the records of 40 eyes of 39 PCV patients (28 men, 11 women) who underwent PDT. The follow-up period ranged from 12 to 42 months. Best-corrected visual acuity (BCVA) improved more than 0.2 logarithm of the minimum angle of resolution (logMAR) units at the final examination in 22 (55%) of the 40 eyes, which were classified into the "Improved group." The other 18 eyes with improvement of <or=0.2 logMAR units were classified into the "Not Improved group."


RESULTS
The baseline MD in the Improved group was significantly better than that in the Not Improved group (P=0.0144). Multivariate analysis confirmed that only the baseline MD was associated with improvement of the final BCVA, showing that eyes with better baseline MD tended to exhibit improvement of the final BCVA after PDT for PCV (odds ratio=1.303; 95% confidence interval, 1.069-1.588).


CONCLUSIONS
The baseline MD in Humphrey perimetry can be useful for predicting visual improvement after PDT for PCV.
Imasawa
Mitsuhiro
M
Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan. mimasawa@yamanashi.ac.jp.|Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. mimasawa@yamanashi.ac.jp.
Tsumura
Toyoaki
T
Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Sekine
Arata
A
Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Kikuchi
Toyohiko
T
Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Iijima
Hiroyuki
H
Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
D000368:Aged; D000369:Aged, 80 and over; D002829:Choroid / Q000098:blood supply*; D015862:Choroid Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology*; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin